Stage, Pancreatic CancerMPMNCT02900950
Multicolour Versus Monocolour Specimens Inking After Pancreaticoduodenectomy for Periampullary Cancer
A study testing Multicolour inking specimens and Monocolour inking specimens in people with Stage, Pancreatic Cancer and Neoplasm, Residual, run by IRCCS Azienda Ospedaliero-Universitaria di Bologna at 1 site in Italy.
Trial summary
A single-centre, randomised clinical trial of patients affected by periampullary cancer who underwent pancreaticoduodenectomies which included two different types of specimen margination: arm A (multicolour inking) and arm B (monocolour inking). Read more about this study
- Who is it for?
- Ages 18 to 80 years
- Conditions the study is for
- Stage, Pancreatic Cancer, Neoplasm, Residual, Pancreatic Neoplasm
- What is being tested?
- Multicolour inking specimens and Monocolour inking specimens
- Type of treatment
- Surgery or procedure
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 68 participants
- Where
- 1 siteItaly
- Study dates
- Jun 2012to Jan 2016
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 80 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- medical history without previous pancreatic resection or pancreatic cancer
- written consent
Who cannot join
- patients previously treated with chemotherapy radiotherapy or chemoradiotherapy for pancreatic cancer
- patients with diagnostic doubts of chronic pancreatitis, serous cystic tumours, intraductal papillary mucinous tumours or neuroendocrine tumours
- patients unresectable at laparotomy
- patients who had undergone other pancreatic resections (total or subtotal pancreatectomy).
Trial locations and contacts
1 site in 1 country.
Italy1 site
S.Orsola-Malpighi Hospital, University of Bologna
Bologna, Bologna, 40138
About this study
Official title: Multicolour Versus Monocolour Inking Specimens After Pancreaticoduodenectomy for Periampullary Cancer: a Single Center Prospective Randomised Clinical Trial.
A single-centre, randomised clinical trial of patients affected by periampullary cancer who underwent pancreaticoduodenectomies which included two different types of specimen margination: arm A (multicolour inking) and arm B (monocolour inking). The randomisation of the specimen was made after the resection, blinded for the surgeons involved in the operation. The primary endpoint was the overall R1 resection rate and its difference between the two arms. The secondary endpoints were the R1 resection rate in each margin and its difference between the two arms, and the impact of margin status on survival. A sample size of 18 patients was required.
Read the detailed description
This study was a single-centre, prospective, controlled, open, parallel group, randomised clinical trial, conducted in the tertiary referral University Centre of S.Orsola-Malpighi Hospital, Bologna, Italy, from June 2012 to January 2016, which enrolled patients affected by periampullary cancer who underwent pancreaticoduodenectomy (PD). All patients with suspected periampullary cancer were enrolled in the study, but only patients who underwent pancreaticoduodenectomy were randomised and allocated to a multicolour inking specimen (arm A, experimental) or a monocolour inking (arm B, control) after specimen was taken out from the operative field. The analysis regarded only the specimens of the patients who underwent PD in which the final pathologic report showed a diagnosis of invasive periampullary cancer (pancreatic, ampullary and distal bile duct).
After performing the pancreaticoduodenectomies, the surgeon intraoperatively inked the surfaces/margins of the specimen with different colours. In the multicolour arm, the surfaces/margins inked were the following: Anterior surface of the pancreas (yellow); Posterior surface of the pancreas (orange); Superior mesenteric/portal vein groove (blu); Superior mesenteric artery margin (retroperitoneal margin) (red); Transection margin of the bile duct (green).The trans-section pancreatic and gastric margins were not inked.
In the monocolour arm, only the superior mesenteric artery margin and the pancreatic margin were intraoperatively indicated by the surgeon in the specimen: a single stitch to identify the transection pancreatic margin and a continuous suture to identify the superior mesenteric artery margin. Monochromatic inking of the superior mesenteric artery margin was subsequently carried out by the pathologist. In both arms of treatment, the macroscopic evaluation and slicing of the surgical specimen followed the Leeds Pathology Protocol (LEEPP), and seven margins, which included the anterior, posterior, superior mesenteric /portal vein groove, superior mesenteric artery, bile duct, pancreatic neck and stomach margins, were examined. The primary endpoint was to evaluate the overall R1 resection rate and its difference between multicolour (arm A) and monocolour (arm B) inking of the specimen. The secondary endpoints were to evaluate the R1 resection rate in each margin: anterior and posterior surfaces of the pancreatic head; superior mesenteric/portal vein groove; superior mesenteric artery margin; transection pancreatic and bile duct margins, and its difference between the two arms compared. Finally, the impact of the margin status on survival was considered for each margin and type of periampullary tumours.
Calculation of the sample size was based on the literature assumption that the overall incidence rate expected of R1 ranged from 10 to 76% while it increased to 81-85% when a standardised pathological technique and margination with multicolour inking, as described in arm A, was performed. To detect a difference in R1 rate between these values with a 5% alpha-error and a 80% beta-error at a two-sided 0.05 significance level, a sample size of 18 patients was required for each group. In relation to the fact that the patients were often randomised without a preoperative biopsy, and that following current literature the 5-13% of the presumed malignancies were benign, it was decided to randomise 25 patients in order to avoid a sample size smaller than expected. The sample size calculation was carried out using PS Power and Sample Size Calculation software (Department of Biostatistics; Vanderbilt University; Nashville, TN, USA).
- Being tested
- Multicolour inking specimens, Monocolour inking specimens
- Keywords
- cancer, resection margin, pathology, pancreas
- Medical subject headings
- Pancreatic Neoplasms, Neoplasm, Residual, Neoplasms, Margins of Excision
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Multicolour inking specimensProcedure or surgery
Monocolour inking specimensProcedure or surgery
| Study group | Role | What they receive |
|---|---|---|
| Arm A-Multicolour inking specimen | Experimental | After performing the pancreaticoduodenectomies, the surgeon intraoperatively inked the surfaces/margins of the specimen with different colours. The surfaces/margins inked were the following:
1. Anterior surface of the pancreas (yellow);
2. Posterior surface of the pancreas (orange);
3. Superior mesenteric/portal vein groove (blu);
4. Superior mesenteric artery margin (retroperitoneal margin) (red);
5. Transection margin of the bile duct (green) The trans-section pancreatic and gastric margins were not inked. Receives: Procedure: Multicolour inking specimens |
| Arm B-Monocolour inking specimen | Other | In arm B, only the superior mesenteric artery margin and the pancreatic margin were intraoperatively indicated by the surgeon in the specimen: a single stitch to identify the transection pancreatic margin and a continuous suture to identify the superior mesenteric artery margin. Monochromatic inking of the superior mesenteric artery margin was subsequently carried out by the pathologist. Receives: Procedure: Monocolour inking specimens |
What is being measured
The primary outcome is the main question the study is designed to answer.
Evaluate overall microscopic resection margins involvement (R1 rate) after pancreaticoduodenectomy for periampullary cancer.
Microscopic margin involvement (R1) was defined as a distance of the tumour from the resection margin of ≤1 mm.
Measured: At the time of pathological examination
Evaluate R1 rate differences between multicolour and monocolour inking of the specimen
Microscopic margin involvement (R1) was defined as a distance of the tumour from the resection margin of ≤1 mm.
Measured: At the time of pathological examination
Secondary outcomes (8)
Evaluate R1 resection rate in anterior surface of the pancreatic head.
Microscopic margin involvement (R1) was defined as a distance of the tumour from the resection margin of ≤1 mm.
Measured: At the time of pathological examination
Evaluate R1 resection rate in posterior surface of the pancreatic head.
Microscopic margin involvement (R1) was defined as a distance of the tumour from the resection margin of ≤1 mm.
Measured: At the time of pathological examination
Evaluate R1 resection rate in superior mesenteric/portal vein groove
Microscopic margin involvement (R1) was defined as a distance of the tumour from the resection margin of ≤1 mm.
Measured: At the time of pathological examination
Evaluate R1 resection rate in superior mesenteric artery margin
Microscopic margin involvement (R1) was defined as a distance of the tumour from the resection margin of ≤1 mm.
Measured: At the time of pathological examination
Evaluate R1 resection rate in pancreatic transection margin
Microscopic margin involvement (R1) was defined as a distance of the tumour from the resection margin of ≤1 mm.
Measured: At the time of pathological examination
Evaluate R1 resection rate in common bile duct margin
Microscopic margin involvement (R1) was defined as a distance of the tumour from the resection margin of ≤1 mm.
Measured: At the time of pathological examination
Disease Free Survival and Overall Survival of the participants
Disease Free Survival and Overall Survival of the participants are measured using Kaplan-Meier curves.
Measured: Through study completion, an average of 6 months
Relation between Disease Free Survival and Overall Survival of the participants and R status
Disease Free Survival and Overall Survival of the participants are measured using Kaplan-Meier curves and divided in subgroups related to their margin status (R0 versus R1).
Measured: Through study completion, an average of 6 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted15 Sep 2016 (estimated)
- Study startJun 2012
- Primary completionJan 2016
- Study completionJan 2016
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Stage, Pancreatic CancerStudies of the same condition, open and under way.
- More trials run by IRCCS Azienda Ospedaliero-Universitaria di BolognaThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Diagnosis
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind
- Who is masked
- Participant, Care provider
- Enrolment
- 68 participants (actual)
Sponsor and investigators
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Riccardo Casadei, IRCCS Azienda Ospedaliero-Universitaria di Bologna
- Investigators
- Riccardo Casadei, Professor, Principal investigator, S. Orsola-Malpighi Hospita, University of Bologna, Italy
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02900950
- Sponsor's protocol ID
- MPM-DCP
- Acronym
- MPM
- Status last verified
- Sep 2016
- First submitted
- 1 Sep 2016
- Last updated
- 15 Sep 2016
- Results posted
- No
- Data monitoring committee
- Yes
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 15 Sep 2016. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Multicolour Versus Monocolour Inking Specimens After Pancreaticoduodenectomy for Periampullary Cancer: a Single Center Prospective Randomised Clinical Trial.
- ClinicalTrials.gov ID
- NCT02900950
- Acronym / sponsor ID
- MPM / MPM-DCP
- Keywords
- cancer, resection margin, pathology, pancreas
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 68 participants (actual)
- Lead sponsor
- IRCCS Azienda Ospedaliero-Universitaria di BolognaUniversity, hospital or other
- Study start
- Jun 2012
- Primary completion
- Jan 2016 (actual)
- Study completion
- Jan 2016 (actual)
- First posted
- 15 Sep 2016 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
A single-centre, randomised clinical trial of patients affected by periampullary cancer who underwent pancreaticoduodenectomies which included two different types of specimen margination: arm A (multicolour inking) and arm B (monocolour inking). The randomisation of the specimen was made after the resection, blinded for the surgeons involved in the operation. The primary endpoint was the overall R1 resection rate and its difference between the two arms. The secondary endpoints were the R1 resection rate in each margin and its difference between the two arms, and the impact of margin status on survival. A sample size of 18 patients was required.
Detailed description
This study was a single-centre, prospective, controlled, open, parallel group, randomised clinical trial, conducted in the tertiary referral University Centre of S.Orsola-Malpighi Hospital, Bologna, Italy, from June 2012 to January 2016, which enrolled patients affected by periampullary cancer who underwent pancreaticoduodenectomy (PD). All patients with suspected periampullary cancer were enrolled in the study, but only patients who underwent pancreaticoduodenectomy were randomised and allocated to a multicolour inking specimen (arm A, experimental) or a monocolour inking (arm B, control) after specimen was taken out from the operative field. The analysis regarded only the specimens of the patients who underwent PD in which the final pathologic report showed a diagnosis of invasive periampullary cancer (pancreatic, ampullary and distal bile duct).
After performing the pancreaticoduodenectomies, the surgeon intraoperatively inked the surfaces/margins of the specimen with different colours. In the multicolour arm, the surfaces/margins inked were the following: Anterior surface of the pancreas (yellow); Posterior surface of the pancreas (orange); Superior mesenteric/portal vein groove (blu); Superior mesenteric artery margin (retroperitoneal margin) (red); Transection margin of the bile duct (green).The trans-section pancreatic and gastric margins were not inked.
In the monocolour arm, only the superior mesenteric artery margin and the pancreatic margin were intraoperatively indicated by the surgeon in the specimen: a single stitch to identify the transection pancreatic margin and a continuous suture to identify the superior mesenteric artery margin. Monochromatic inking of the superior mesenteric artery margin was subsequently carried out by the pathologist. In both arms of treatment, the macroscopic evaluation and slicing of the surgical specimen followed the Leeds Pathology Protocol (LEEPP), and seven margins, which included the anterior, posterior, superior mesenteric /portal vein groove, superior mesenteric artery, bile duct, pancreatic neck and stomach margins, were examined. The primary endpoint was to evaluate the overall R1 resection rate and its difference between multicolour (arm A) and monocolour (arm B) inking of the specimen. The secondary endpoints were to evaluate the R1 resection rate in each margin: anterior and posterior surfaces of the pancreatic head; superior mesenteric/portal vein groove; superior mesenteric artery margin; transection pancreatic and bile duct margins, and its difference between the two arms compared. Finally, the impact of the margin status on survival was considered for each margin and type of periampullary tumours.
Calculation of the sample size was based on the literature assumption that the overall incidence rate expected of R1 ranged from 10 to 76% while it increased to 81-85% when a standardised pathological technique and margination with multicolour inking, as described in arm A, was performed. To detect a difference in R1 rate between these values with a 5% alpha-error and a 80% beta-error at a two-sided 0.05 significance level, a sample size of 18 patients was required for each group. In relation to the fact that the patients were often randomised without a preoperative biopsy, and that following current literature the 5-13% of the presumed malignancies were benign, it was decided to randomise 25 patients in order to avoid a sample size smaller than expected. The sample size calculation was carried out using PS Power and Sample Size Calculation software (Department of Biostatistics; Vanderbilt University; Nashville, TN, USA).
Study design
- Primary purpose
- Diagnosis
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind (participant, care provider)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Arm A-Multicolour inking specimen | Experimental | Procedure: Multicolour inking specimensAfter performing the pancreaticoduodenectomies, the surgeon intraoperatively inked the surfaces/margins of the specimen with different colours. The surfaces/margins inked were the following: 1. Anterior surface of the pancreas (yellow); 2. Posterior surface of the pancreas (orange); 3. Superior mesenteric/portal vein groove (blu); 4. Superior mesenteric artery margin (retroperitoneal margin) (red); 5. Transection margin of the bile duct (green) The trans-section pancreatic and gastric margins were not inked. |
| Arm B-Monocolour inking specimen | Other | Procedure: Monocolour inking specimensIn arm B, only the superior mesenteric artery margin and the pancreatic margin were intraoperatively indicated by the surgeon in the specimen: a single stitch to identify the transection pancreatic margin and a continuous suture to identify the superior mesenteric artery margin. Monochromatic inking of the superior mesenteric artery margin was subsequently carried out by the pathologist. |
Who may qualify
- Ages
- 18 to 80 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (2 listed)
- medical history without previous pancreatic resection or pancreatic cancer
- written consent
Key exclusion criteria (4 listed)
- patients previously treated with chemotherapy radiotherapy or chemoradiotherapy for pancreatic cancer
- patients with diagnostic doubts of chronic pancreatitis, serous cystic tumours, intraductal papillary mucinous tumours or neuroendocrine tumours
- patients unresectable at laparotomy
- patients who had undergone other pancreatic resections (total or subtotal pancreatectomy).
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Multicolour inking specimens | Procedure or surgery | Arm A-Multicolour inking specimen |
| Monocolour inking specimens | Procedure or surgery | Arm B-Monocolour inking specimen |
Primary outcome
Evaluate overall microscopic resection margins involvement (R1 rate) after pancreaticoduodenectomy for periampullary cancer.
Time frame: At the time of pathological examination
Microscopic margin involvement (R1) was defined as a distance of the tumour from the resection margin of ≤1 mm.
Evaluate R1 rate differences between multicolour and monocolour inking of the specimen
Time frame: At the time of pathological examination
Microscopic margin involvement (R1) was defined as a distance of the tumour from the resection margin of ≤1 mm.
8 secondary outcomes
Evaluate R1 resection rate in anterior surface of the pancreatic head.
Time frame: At the time of pathological examination
Evaluate R1 resection rate in posterior surface of the pancreatic head.
Time frame: At the time of pathological examination
Evaluate R1 resection rate in superior mesenteric/portal vein groove
Time frame: At the time of pathological examination
Evaluate R1 resection rate in superior mesenteric artery margin
Time frame: At the time of pathological examination
Evaluate R1 resection rate in pancreatic transection margin
Time frame: At the time of pathological examination
Evaluate R1 resection rate in common bile duct margin
Time frame: At the time of pathological examination
Disease Free Survival and Overall Survival of the participants
Time frame: Through study completion, an average of 6 months
Relation between Disease Free Survival and Overall Survival of the participants and R status
Time frame: Through study completion, an average of 6 months
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 15 Sep 2016.
- Individual participant dataSharing planned: No
Related trials for Stage, Pancreatic Cancer
RecruitingPhase 3
Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma
Pancreatic Cancer, Pancreatic Cancer Metastatic
RecruitingPhase 3
Lanreotide Versus Placebo Before Surgery to Prevent a Surgical Complication Called a Pancreatic Fistula
Pancreatic Carcinoma, Pancreatic Neoplasm
RecruitingPhase 3
Study of Zoldonrasib + Chemo of Investigator's Choice vs Placebo + Chemo of Investigator's Choice as First-line Treatment in Metastatic KRAS G12D-mutated Pancreatic Adenocarcinoma ( RASolute 305 )
Pancreatic Cancer, Pancreatic Cancer Metastatic
Recruiting
CREO - Microwave Ablation Feasibility Study
Pancreatic Cancer, Liver Cancer (Locally Advanced or Metastatic)
RecruitingPhase 1
A Study of ERAS-0015 in Patients With Advanced or Metastatic Solid Tumors
Metastatic Solid Tumors
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Riccardo Casadei, Professor principal investigator
S. Orsola-Malpighi Hospita, University of Bologna, Italy
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Multicolour inking specimens and Monocolour inking specimens in people with Stage, Pancreatic Cancer and Neoplasm, Residual, run by IRCCS Azienda Ospedaliero-Universitaria di Bologna at 1 site in Italy.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 15 Sep 2016. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Italy. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Evaluate overall microscopic resection margins involvement (R1 rate) after pancreaticoduodenectomy for periampullary cancer. (time frame: At the time of pathological examination). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 15 Sep 2016.